Influence of MBL-2 mutations in the infection risk of patients with follicular lymphoma treated with rituximab, fludarabine, and cyclophosphamide.
The employment of current treatments based on chemotherapy and immunotherapy leads to inmunosuppression. The presence of mutations or polymorphisms in genes related to immune system might involve an additional disadvantage. The aim of the present study was to analyze mannose-binding lectin (MBL-2 gene) mutations and their association with severe infections and event-free survival in patients diagnosed with follicular lymphoma, treated uniformly, in the clinical trial LNHF-03. The results of this trial showed impressive clinical efficacy but was complicated with 80 documented infectious episodes. Patients were classified into two genotypic groups, AA and AO/OO, based on their haplotypic inheritance. Neither the number of infectious episodes nor differences in event-free survival was found as a function of MBL-2 groups. Other factors, including the lymphoma malignancy and the immune alterations associated with the disease, should be considered responsible for this observation.
Martínez-López
Joaquin
J
Hospital 12 de Octubre, Madrid, Spain. jmartinezlo@yahoo.es
Rivero
Ana
A
Rapado
Inmaculada
I
Montalbán
Carlos
C
Paz-Carreira
Jose
J
Canales
Miguel
M
Martínez
Rafael
R
Sánchez-Godoy
Pedro
P
Fernández de Sevilla
Alberto
A
Peñalver
Francisco J
FJ
Gonzalez
Marcos
M
Prieto
Elena
E
Salar
Antonio
A
Burgaleta
Carmen
C
Queizán
Jose A
JA
Peñarrubia
Maria J
MJ
Monteagudo
Maria D
MD
Cabrera
Carmen
C
De la Serna
Javier
J
Tomás
José F
JF
D000328:Adult; D000368:Aged; D000483:Alleles; D000890:Anti-Infective Agents / Q000627:therapeutic use; D000911:Antibodies, Monoclonal / Q000008:administration & dosage / Q000009:adverse effects; D058846:Antibodies, Monoclonal, Murine-Derived; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D017322:Clinical Trials, Phase II as Topic / Q000706:statistics & numerical data; D003520:Cyclophosphamide / Q000008:administration & dosage / Q000009:adverse effects; D057239:Early Termination of Clinical Trials; D005260:Female; D005787:Gene Frequency; D020022:Genetic Predisposition to Disease; D014644:Genetic Variation; D006239:Haplotypes / Q000235:genetics; D006801:Humans; D007239:Infections / Q000453:epidemiology* / Q000209:etiology / Q000235:genetics; D008224:Lymphoma, Follicular / Q000188:drug therapy / Q000453:epidemiology / Q000235:genetics*; D008231:Lymphopenia / Q000139:chemically induced / Q000150:complications; D008297:Male; D037601:Mannose-Binding Lectin / Q000235:genetics*; D008875:Middle Aged; D015337:Multicenter Studies as Topic; D009503:Neutropenia / Q000139:chemically induced / Q000150:complications; D011446:Prospective Studies; D012306:Risk; D000069283:Rituximab; D013030:Spain / Q000453:epidemiology; D014740:Vidarabine / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives; D055815:Young Adult
D000890:Anti-Infective Agents; D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; C445619:MBL2 protein, human; D037601:Mannose-Binding Lectin; D000069283:Rituximab; D003520:Cyclophosphamide; D014740:Vidarabine; C024352:fludarabine